Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Competency to understand and sign the IEC/IRB approved informed consent form prior to any study mandated procedure, and willing/able to comply with study requirements~* Age ≥ 18 years~* Current diagnosis of quiescent CD as defined by CDAI score of \< 220~* Current diagnosis of IDA as defined by Hb ≥ 9.5 g/dl and \<12.0 g/dl for women and ≥ 9.5 g/dl and \<13.0 g/dl for men; ferritin \< 30 µg/l~* Prior OFP failure as defined per protocol~* If receiving protocol-allowed immunosuppressant must be on stable dose~* Females of childbearing potential must agree to use a reliable method of contraception~Exclusion Criteria:~* Anaemia due to any cause other than iron deficiency~* Intramuscular or intravenous injection or administration of depot iron preparation, blood infusions, or erythropoietin within 3 months~* Oral iron supplementation use within 1 month~* Use of immunosuppressant with known effect of anaemia induction within 1 month~* Vitamin B12 or Folic Acid injection/infusion within 4 weeks~* Untreated Vitamin B-12 or Folic Acid deficiency~* Known hypersensitivity or allergy to ST10-021 or components of the study medication, or contraindication for treatment with iron preparations~* Other chronic or acute inflammatory or infectious diseases~* Creatinine \> 2.0 mg/dl~* AST or ALT levels ≥ 5 times the upper limit of normal~* Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject~* History of malignancy within the past 5 years (except in situ removal of basal cell carcinoma)~* Significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results~* Participation in another interventional clinical study within 30 days or during the study~* Inmates of a psychiatric ward, prison, or other state institution~* Investigator or any other team member involved directly or indirectly in the conduct of the clinical study~* Scheduled or expected hospitalization and/or surgery during the course of the study~* Females who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ST10 (Type: EXPERIMENTAL): ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete